Peptide Monograph
Epithalon
Epitalon / Epithalone
At a Glance
Mechanism of Action
Epithalon (also known as Epitalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin, a polypeptide extract derived from the bovine pineal gland.[1]
The primary mechanism of interest is Epithalon's ability to activate telomerase, specifically the catalytic subunit human telomerase reverse transcriptase (hTERT). Telomerase is the enzyme responsible for adding telomeric repeats (TTAGGG) to chromosome ends, counteracting the progressive telomere shortening that occurs with each cell division. Khavinson and colleagues demonstrated that Epithalon induces telomerase activity in human somatic cells in vitro, resulting in elongation of telomeres beyond the critical length that normally triggers replicative senescence.[2]
Epithalon also acts on the pineal gland, stimulating the production and secretion of melatonin. In aging organisms, pineal function declines and melatonin output decreases. Animal studies have shown that Epithalon administration restores melatonin production toward youthful levels, which may contribute to the normalization of circadian rhythm and neuroendocrine function observed in treated animals.[3]
Additionally, Epithalon demonstrates antioxidant properties, upregulating the activity of endogenous antioxidant enzymes including superoxide dismutase (SOD) and glutathione peroxidase. This antioxidant activity may reduce oxidative damage to DNA, proteins, and lipids, contributing to cellular protection independent of the telomerase pathway.[4]
The peptide has also been reported to influence gene expression related to cell cycle regulation and apoptosis, potentially modulating the balance between cellular proliferation and programmed cell death in aging tissues.[1]
Evidence Summary
The majority of Epithalon research originates from a single research group (Khavinson and colleagues) and has been published primarily in Russian-language journals or lower-impact English-language outlets. No human clinical trials on longevity endpoints have been published in Western peer-reviewed journals. Independent replication of the key findings remains limited. Readers should weigh this limitation heavily when evaluating the evidence presented below.
In Vitro Studies
Khavinson et al. demonstrated that Epithalon activates telomerase in human fetal fibroblast cell cultures, leading to elongation of telomeres and an increase in the number of cell divisions beyond the Hayflick limit. Treated cells underwent an additional 10 passages compared to untreated controls while maintaining normal karyotype and cell morphology.[2] Telomerase activation has also been confirmed in human pulmonary fibroblasts and other somatic cell lines treated with Epithalon in vitro.[5]
Animal Studies
Anisimov et al. conducted lifespan studies in female CBA mice and demonstrated that chronic Epithalon administration resulted in a 13.3% increase in mean lifespan compared to controls. Treated mice also showed reduced incidence of chromosome aberrations in bone marrow cells and a trend toward reduced tumor incidence, though the latter did not reach statistical significance in all studies.[3]
Additional animal studies reported restoration of melatonin secretion in aged rats and monkeys, normalization of cortisol rhythms, and improvement in reproductive function in aged female rats. Khavinson and colleagues have also reported immunomodulatory effects, including enhanced T-cell function in aged animals.[4][1]
Human Evidence
No completed, peer-reviewed, randomized controlled human clinical trials of Epithalon on longevity endpoints have been published in major Western journals. Some Russian-language publications describe observational studies in elderly patients receiving epithalamin (the pineal extract from which Epithalon was derived), reporting improved immune markers and reduced mortality over multi-year follow-up periods, but these studies do not meet current standards for clinical evidence due to methodological limitations including lack of randomization, blinding, and adequate controls.[1]
Anecdotal reports from self-experimenters describe subjective improvements in sleep quality, energy, and skin appearance, but these cannot be considered reliable evidence.
Primary Uses (in Research)
Based on the available preclinical literature, Epithalon has been investigated for the following applications:
- Telomerase activation and telomere elongation — The primary research focus. In vitro data demonstrates activation of hTERT and extension of replicative lifespan in human somatic cells.[2]
- Anti-aging and longevity — Animal studies suggest modest lifespan extension in mice, potentially mediated by reduced genomic instability and improved neuroendocrine function.[3]
- Melatonin restoration — Stimulation of pineal gland melatonin production in aged organisms, with potential downstream effects on circadian rhythm normalization and sleep quality.[4]
- Antioxidant defense enhancement — Upregulation of endogenous antioxidant enzyme activity, potentially reducing age-related oxidative damage.[4]
- Immunomodulation — Improvement of T-cell function and immune competence in aged animal models.[1]
Contraindications
No established human contraindications exist because insufficient clinical data is available. The following precautions are based on the peptide's known pharmacological mechanisms and represent theoretical concerns:
- Pregnancy and lactation — No reproductive toxicology or teratogenicity studies have been conducted in humans. No safety data exists for use during pregnancy or breastfeeding. Use is strongly discouraged.
- Active malignancy — Epithalon activates telomerase, an enzyme that is upregulated in approximately 85–90% of human cancers. Exogenous telomerase activation could theoretically promote cancer cell immortalization or accelerate tumor growth. Individuals with active cancer or a history of cancer should avoid use.
- Autoimmune conditions — Given Epithalon's immunomodulatory properties, individuals with active autoimmune diseases should exercise caution, as immune stimulation could exacerbate autoimmune flares.
- Pediatric use — No safety or efficacy data exists for use in children or adolescents. Telomerase is already active in developing tissues, and exogenous activation is not warranted.
- Known hypersensitivity — Discontinue use if signs of allergic reaction (rash, urticaria, angioedema, dyspnea) develop.
Standard Protocols
The following protocols are derived from animal study dosing extrapolations and community-reported protocols. No dosing regimen has been validated in human clinical trials. These should not be interpreted as medical prescriptions.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Standard anti-aging cycle | SubQ | 5 – 10 mg | 1x daily | 10–20 days, repeat 2–3x/year |
| Conservative protocol | SubQ | 5 mg | 1x daily | 10 days, repeat every 4–6 months |
| Intensive protocol | SubQ or IV | 10 mg | 1x daily | 20 days, repeat 2x/year |
Common Stacks & Synergies
In the peptide research and self-experimentation community, Epithalon is sometimes combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined use:
- Epithalon + Thymalin — Both developed by Khavinson's group. The rationale is that Epithalon targets telomere and pineal function while Thymalin supports thymic immune function. Some animal data suggests complementary anti-aging effects, but no controlled human studies exist.
- Epithalon + Melatonin — Some practitioners supplement with exogenous melatonin alongside Epithalon, though Epithalon itself stimulates endogenous melatonin production. The rationale for combining is poorly defined.
- Epithalon + GHK-Cu — Copper peptide GHK-Cu is used for tissue remodeling and gene expression modulation. The theoretical synergy involves complementary anti-aging mechanisms targeting different cellular pathways.
Preparation & Administration
Epithalon is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 10 mg or 50 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.
Reconstitution
For a standard 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 500 mcg. Adjust reconstitution volume to achieve desired concentration. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Typical injection sites include the abdominal area or upper arm. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Side Effects & Adverse Events
The adverse event profile described below is drawn from animal studies and uncontrolled self-reports. Without formal human clinical trials, the true incidence and severity of side effects cannot be established.
Published animal studies report no significant toxicity at the doses used in lifespan experiments. Khavinson and colleagues describe Epithalon as well-tolerated in animal models, with no observed organ toxicity or lethal dose identified in preclinical work.[1][3]
Self-reported side effects from community use (unverified):
- Injection site redness, swelling, or mild pain (most commonly reported)
- Improved sleep quality and vivid dreams (frequently reported, may be related to melatonin stimulation)
- Mild headache (infrequent)
- Transient fatigue or drowsiness (rare)
The theoretical long-term risk of telomerase activation in the context of occult or subclinical malignancy remains the most significant safety concern, though this has not been observed in published animal longevity studies.[3]
Drug Interactions
No formal drug interaction studies have been conducted with Epithalon in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:
- Immunosuppressants (cyclosporine, tacrolimus, mycophenolate) — Epithalon's immunomodulatory properties could theoretically counteract the effects of immunosuppressive medications. Exercise caution in transplant recipients or individuals on immunosuppressive therapy.
- Sedatives and hypnotics — Given Epithalon's stimulation of melatonin production, additive sedative effects are theoretically possible when combined with benzodiazepines, Z-drugs, or exogenous melatonin.
- Chemotherapeutic agents — Telomerase activation could theoretically interfere with anti-cancer therapies that depend on telomere attrition for efficacy. Co-administration with chemotherapy is strongly discouraged.
- Anticoagulants — No specific interaction data exists, but as with any injectable peptide, monitoring is advisable for patients on anticoagulant therapy.
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Room temperature (below 25°C / 77°F), away from direct light | Stable for extended periods (months to years if sealed) |
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Optimal for long-term storage |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 21 days |
| Reconstituted solution | Room temperature | Not recommended; use within 24–48 hours if unavoidable |
Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption."
- EMA (European Union) — Not approved as a medicinal product. Regulatory status varies by member state. Generally available as a research chemical.
- Russia — Epithalamin (the pineal extract predecessor) has been used in clinical practice in Russia, but the synthetic Epithalon peptide itself does not hold formal regulatory approval as a drug in most contexts.
- WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026, but could potentially fall under S0 ("non-approved substances") depending on interpretation.
- Australia (TGA) — Not approved. Likely classified as a prescription-only substance under the Poisons Standard.
- Not scheduled — Epithalon is not classified as a controlled substance in any major jurisdiction. It occupies a legal gray area, legal to purchase for research purposes but not legal to market for human therapeutic use.
Open Questions
Significant gaps remain in the Epithalon evidence base. Key unresolved questions include:
- Absence of Western peer-reviewed human trials — The most fundamental limitation. No RCTs on longevity or telomere endpoints have been published in high-impact, peer-reviewed Western journals.
- Independent replication — The majority of published data comes from a single research group. Independent validation of key claims (telomerase activation, lifespan extension) by other laboratories is needed.
- Cancer risk — Telomerase activation is a hallmark of cancer biology. While animal studies have not shown increased tumor incidence, the long-term oncogenic risk of periodic telomerase activation in humans is unknown.
- Dose-response relationship — Optimal dosing in humans has not been established. Current protocols are extrapolated from animal studies with inherent uncertainty in interspecies scaling.
- Duration of effect — How long telomerase activation persists after a treatment cycle, and whether periodic re-dosing is necessary or sufficient for meaningful telomere maintenance, remains unclear.
- Purity and quality control — As an unregulated research chemical, the purity, sterility, and accurate labeling of commercially available Epithalon products cannot be guaranteed.
Bibliography
- Khavinson VKh. "Peptides and Ageing." Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID:12374906.
- Khavinson VKh, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med. 2003;135(6):590-2. doi:10.1023/A:1025493705728. PMID:12937682.
- Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology. 2003;4(4):193-202. doi:10.1023/A:1025114230714. PMID:14501183.
- Khavinson VKh, Izmaylov DM, Obukhova LK, Malinin VV. "Effect of epitalon on the lifespan increase in Drosophila melanogaster." Mech Ageing Dev. 2000;120(1-3):141-9. doi:10.1016/S0047-6374(00)00217-7. PMID:11087911.
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. "Peptide promotes overcoming of the division limit in human somatic cell." Bull Exp Biol Med. 2004;137(5):503-6. doi:10.1023/B:BEBM.0000038164.49947.8c. PMID:15455129.